Table 6.
Adverse events reported by ≥ 2% of subjects in any treatment group (ITT population), n (%)
| Latanoprost concentration (μg/mL) | ||||
|---|---|---|---|---|
| |
50 |
75 |
100 |
125 |
| N |
71 |
70 |
72 |
69 |
|
Eye disorders | ||||
| Abnormal sensation in eye |
3 (4.2) |
4 (5.7) |
7 (9.7) |
4 (5.8) |
| Anterior chamber disorder NOS |
0 (0.0) |
2 (2.9) |
2 (2.8) |
1 (1.4) |
| Conjunctival disorder NOS |
2 (2.8) |
1 (1.4) |
0 (0.0) |
0 (0.0) |
| Conjunctival edema |
0 (0.0) |
2 (2.9) |
2 (2.8) |
0 (0.0) |
| Conjunctival hyperemia |
12 (16.9) |
13 (18.6) |
15 (20.8) |
11 (15.9) |
| Dry eye NEC |
1 (1.4) |
2 (2.9) |
4 (5.6) |
0 (0) |
| Eye irritation |
5 (7.0) |
7 (10.0) |
6 (8.3) |
8 (11.6) |
| Eye pain |
2 (2.8) |
6 (8.6) |
3 (4.2) |
4 (5.8) |
| Eyelid disorder NOS |
0 (0.0) |
2 (2.9) |
0 (0.0) |
0 (0.0) |
| Keratitis NEC |
2 (2.8) |
4 (5.7) |
3 (4.2) |
3 (4.3) |
| Ocular hyperemia* |
5 (7.0) |
4 (5.7) |
5 (6.9) |
2 (2.9) |
| Red eye |
3 (4.2) |
5 (7.1) |
6 (8.3) |
2 (2.9) |
| Vision blurred |
1 (1.4) |
0 (0.0) |
2 (2.8) |
3 (4.3) |
|
Musculoskeletal, connective tissue and bone disorders | ||||
| Arthralgia |
1 (1.4) |
0 (0.0) |
2 (2.8) |
1 (1.4) |
|
Nervous system disorders | ||||
| Headache NOS | 4 (5.6) | 4 (5.7) | 3 (4.2) | 4 (5.8) |
ITT intention-to-treat, NEC not elsewhere classified, NOS not otherwise specified.
*Includes conjunctival hyperemia where investigator specified it as bulbar or palpebral.